Recruiting
PHASE2
INTERVENTIONAL
NCT06143956
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. The results for the CWMM screening record will be reported when all the ISA's complete.
Interventions
Name:
LY3305677
Type:
DRUG
Description:
Administered SC. ISA specific interventions will be listed in the ISA.
Name:
LY3841136
Type:
DRUG
Description:
Administered SC. ISA specific interventions will be listed in the ISA.
Name:
Tirzepatide
Type:
DRUG
Description:
Administered SC. ISA specific interventions will be listed in the ISA.
Name:
Placebo
Type:
DRUG
Description:
Administered SC. ISA specific interventions will be listed in the ISA.
Name:
LY3549492
Type:
DRUG
Description:
Administered orally. ISA specific interventions will be listed in the ISA.
Primary Outcomes
Measure:
Number of Participants Allocated to Each ISA
TimeFrame:
Baseline to Week 48
Description:
Each ISA will detail the intervention specific analysis.
Trial Information
NCT ID
NCT06143956
Status
Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025